Abbisko Cayman Ltd
HKEX:2256
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.17
5.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Abbisko Cayman Ltd
Abbisko Cayman Ltd
Accrued Liabilities
Abbisko Cayman Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abbisko Cayman Ltd
HKEX:2256
|
Accrued Liabilities
¥27.9m
|
CAGR 3-Years
47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accrued Liabilities
¥2.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Accrued Liabilities
¥134.4m
|
CAGR 3-Years
57%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accrued Liabilities
¥268.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Accrued Liabilities
¥164.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
30%
|
CAGR 10-Years
19%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accrued Liabilities
¥325.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
85%
|
CAGR 10-Years
60%
|
|
Abbisko Cayman Ltd
Glance View
Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).
See Also
What is Abbisko Cayman Ltd's Accrued Liabilities?
Accrued Liabilities
27.9m
CNY
Based on the financial report for Dec 31, 2023, Abbisko Cayman Ltd's Accrued Liabilities amounts to 27.9m CNY.
What is Abbisko Cayman Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
47%
Over the last year, the Accrued Liabilities growth was -41%. The average annual Accrued Liabilities growth rates for Abbisko Cayman Ltd have been 47% over the past three years .
You don't have any saved screeners yet
